| Protocol | Title |
|---|---|
| E1F05 | Phase II Study of Rituximab Given in Conjunction with Standard
Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
Activation Date: 21-dec-2006 |
| N0574 | Phase III Randomized Trial of the Role of Whole Brain Radiation
Therapy in Addition to Radiosurgery in PAtients with One to Three
Cerebral Metastases
Activation Date: 08-aug-2006 |
| Protocol | Title |
|---|---|
| 40101 | Cyclophosphamide and Doxorubicin (CA)(4 vs 6 Cycles) Versus
Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in
Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase
III Randomized Study
Activation Date: 15-may-2002 |
| E1104 | A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in
Combination with Trastuzumab (Herceptin) in Patients with Advanced
Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast
Cancer
Activation Date: 23-aug-2006 Suspended: 04-oct-2007 ECOG Participants(requires Adobe Acrobat) |
| E1105 | A Randomized Phase III Double-Blind Placebo-Controlled Trial of
First-line Chemotherapy and Trastuzumab with or without Bevacizumab
for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
Activation Date: 09-nov-2007 |
| E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide
followed by Paclitaxel with Bevacizumab or Placebo in Patients with
Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Activation Date: 02-nov-2007 |
| IBCSG2402 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression
and the Role of Exemestane as Adjuvant Therapies for Premenopausal
Women with Endocrine Responsive Breast Cancer (SOFT)
Activation Date: 04-aug-2003 |
| IBCSG2502 | A Phase III Trial Evaluating the Role of Exemestane Plus GnRH
Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine
Responsive Breast Cancer (TEXT)
Activation Date: 04-aug-2003 Suspended: 30-nov-2007 |
| NCIC-MA.27 | A Randomized Phase III Trial of Exemestane Versus Anastrozole in
Postmenopausal Women with Receptor Positive Primary Breast Cancer
Activation Date: 21-jul-2003 |
| N063D | ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation
Study: A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination
in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Activation Date: 15-feb-2008 |
| PACT1 | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial
Assigning IndividuaLized Options for Treatment: The TAILORx Trial
Activation Date: 07-apr-2006 |
| S0221 | A Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule
AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for
12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or
High-Risk Node Negative Breast Cancer
Activation Date: 14-nov-2003 |
| S0230 | Phase II Trial of LHRH Analog Administration During Chemotherapy to
Reduce Ovarian Failure Following Chemotherapy in Early Stage,
Hormone-Receptor Negative Breast Cancer
Activation Date: 06-jan-2005 |
| S0307 | Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary
Breast Cancer
Activation Date: 15-nov-2005 |
| S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy
versus Maintaining Therapy for Metastatic Breast Cancer Patients who
Have Elevated Circulating Tumor Cell Levels at First Follow Up
Assessment
Activation Date: 01-oct-2006 |
| Protocol | Title |
|---|---|
| E1Y03 | Master Protocol for Pharmacogenetic and Genomic Studies
Activation Date: 15-sep-2004 |
| Protocol | Title |
|---|---|
| CALGB80101 | Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection
of Gastric or Gastroesophageal Adenocarcinoma.
Activation Date: 19-dec-2002 |
| 80403 | Randomized Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic
Esophageal and GE Junction cancer
Activation Date: 27-mar-2007 |
| C80405 | A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin /
5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the
Combination of Bevacizumab and Cetuximab for Patients with Untreated
Metastatic Adenocarcinoma of the Colon or Rectum
Activation Date: 22-sep-2005 Suspended: 06-jun-2008 |
| E2202 | Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility
Study.
Activation Date: 03-mar-2004 |
| E2205 | A Phase II Study to Measure Response Rate and Toxicity of
Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional
5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative
Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of
the Esophagus.
Activation Date: 10-jun-2008 |
| E3204 | Phase II Study of Preoperative Radiation with Concurrent
Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and
Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab
in Patients with Locally Advanced Rectal Cancer
Activation Date: 25-jul-2006 Suspended: 09-jan-2008 ECOG Participants(requires Adobe Acrobat) |
| E3205 | Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and
Radiation in Immunocompetent Patients with Anal Carcinoma
Activation Date: 19-jan-2007 ECOG Participants(requires Adobe Acrobat) |
| E4203 | Phase II Study of Treatment Selection Based Upon Tumor Thymidylate
Synthase Expression in Previously Untreated Patients with Metastatic
Colorectal Cancer
Activation Date: 14-jul-2005 Suspended: 06-may-2008 ECOG Participants(requires Adobe Acrobat) |
| E5202 | A Randomized Phase III Study Comparing 5-FU, Leucovorin and
Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in
Patients with Stage II Colon Cancer at High Risk for Recurrence to
Determine Prospectively the Prognostic Value of Molecular Markers
Activation Date: 04-aug-2005 |
| E5204 | Intergroup Randomized Phase III Study of Postoperative Oxaliplatin,
5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil,
Leucovorin and Bevacizumab for Patients with Stage II or III Rectal
Cancer Receiving Preoperative Chemoradiation
Activation Date: 17-feb-2006 |
| N0147 | A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus
5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab
(C225) after Curative Resection for Patients with Stage III Colon
Cancer
Activation Date: 10-feb-2004 Suspended: 06-jun-2008 |
| NSABPR04 | A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with Preoperative Radiation Therapy and Continuous
Intravenous Infusion (CVI) of 5-Flourouracil (5-FU) in the Treatment
of Patients with Operable Carcinoma of the Rectum
Activation Date: 23-jul-2004 |
| S0518 | A Phase III Prospective Randomized Comparison of Depot Octreotide
Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC
#704865) in Advanced, Poor Prognosis Carcinoid Patients
Activation Date: 10-dec-2007 |
| S0600 | Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab
(NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line
Therapy for Patients with Metastatic Colorectal Cancer who have
Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Activation Date: 22-jun-2007 Suspended: 06-jun-2008 |
| Protocol | Title |
|---|---|
| CALGB90202 | A Randomized, Double Blind, Placebo-Controlled Phase III Study of
Early versus Standard Zoledronic Acid to Prevent Skeletal Related
Events in Men with Prostate Cancer Metastatic to Bone
Activation Date: 09-feb-2004 |
| C90203 | A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen
Deprivation Prior to Radical Prostatectomy versus Immediate Radical
Prostatectomy in Patients with High-Risk, Clinically Localized
Prostate Cancer
Activation Date: 15-dec-2006 |
| E2804 | The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase and
mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib
and Temsirolimus in Advanced Renal Cell Carcinoma
Activation Date: 14-sep-2007 |
| E2805 | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal
Carcinoma
Activation Date: 24-apr-2006 |
| E3803 | A Phase II Study of a Weekly Schedule of BMS-247550 for Patients with
Hormone Refractory Prostate Cancer
Activation Date: 16-sep-2004 ECOG Participants(requires Adobe Acrobat) |
| E3805 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized
Trial for Extensive Disease in Prostate Cancer
Activation Date: 28-jul-2006 |
| E4805 | A Randomized Phase II Study to Determine the Effect of 2 Different
Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell
Carcinoma
Activation Date: 21-dec-2007 ECOG Participants(requires Adobe Acrobat) |
| E5805 | Phase II Trial of E7389 (Halichondrin B Analog), in Patients with
Metastatic Hormone Refractory Prostate Cancer
Activation Date: 29-nov-2006 Suspended: 20-jun-2008 ECOG Participants(requires Adobe Acrobat) |
| JPR11 | A Phase III Study of Active Surveillance Therapy Against Radical
Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer
(START) (Limited institution participation)
Activation Date: 11-jun-2008 |
| R0524 | A PHASE I/II TRIAL OF A COMBINATION OF PACLITAXEL AND TRASTUZUMAB
WITH DAILY IRRADIATION OR PACLITAXEL ALONE WITH DAILY IRRADIATION
FOLLOWING TRANSURETHRAL SURGERY FOR NON-CYSTECTOMY CANDIDATES WITH
MUSCLE-INVASIVE BLADDER CANCER
Activation Date: 09-jan-2007 |
| S0421 | Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo
for Patients with Advanced Hormone Refractory Prostate Cancer
Activation Date: 22-aug-2006 |
| S9346 | Phase III Study of Intermittent Androgen Deprivation in Patients with
Stage D2 Prostate Cancer
Activation Date: 27-mar-1996 |
| Protocol | Title |
|---|---|
| E1302 | Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus
Docetaxel Plus ZD1839 (Iressa, Gefitinib) In Performance Status 2 Or
Previously Treated Patients With Recurrent Or Metastatic Head And
Neck Cancer
Activation Date: 06-aug-2004 |
| E1304 | Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341
(VELCADETM) in Combination with Irinotecan or PS-341 Alone Followed
by the Addition of Irinotecan at Time of Progression in Patients with
Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head
and Neck (SCCHN)
Activation Date: 20-jul-2005 ECOG Participants(requires Adobe Acrobat) |
| Protocol | Title |
|---|---|
| 10403 | AN INTERGROUP PHASE II CLINICAL TRIAL FOR ADOLESCENTS AND YOUNG
ADULTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Activation Date: 14-may-2008 |
| 10404 | A Randomized Phase II Study of Three Fludarabine/Antibody
Combinations for Patients with Symptomatic Previously Untreated
Chronic Lymphocytic Leukemia
Activation Date: 14-may-2008 |
| CALGB10501 | A Phase III Intergroup CLL Study of Asymptomatic Patients with
Untreated Chronic Lymphocytic Leukemia Randomized To Early
Intervention Versus Observation with Later Treatment in the High risk
Genetic Subset with IGVh Unmutated Disease
Activation Date: 22-jan-2008 |
| E1900 | A Phase III Trial in Adult Acute Myeloid Leukemia:Daunorubicin
Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell
Transplantation
Activation Date: 16-dec-2002 |
| E1902 | A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant
for the Treatment of Myelodysplastic Syndromes
Activation Date: 18-may-2005 ECOG Participants(requires Adobe Acrobat) |
| E1904 | A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase,
and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults
with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Activation Date: 29-jun-2006 Suspended: 16-apr-2008 ECOG Participants(requires Adobe Acrobat) |
| E1905 | A Randomized Phase II Trial of Azacitidine with or without the
Histone Deacetylase Inhibitor MS-275 for the Treatment of
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic
type), and Acute Myeloid Leukemia with Multilineage Dysplasia
Activation Date: 18-aug-2006 |
| E2902 | A Phase III Randomized Study of Farnesyl Transferase Inhibitor
R115777 in Acute Myeloid Leukemia (AML) Patients in Second or
Subsequent Remission or Remission after Primary Induction Failure or
Patients over Age 60 in First Remission
Activation Date: 18-aug-2004 |
| E2903 | Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR)
Followed By Campath-1H For Previously Treated Relapsed or Refractory
Patients With Chronic Lymphocytic Leukemia
Activation Date: 16-dec-2004 ECOG Participants(requires Adobe Acrobat) |
| E3903 | Ancillary laboratory protocol for collecting diagnostic material on
patients considered for ECOG treatment trials for leukemia or related
hematologic disorders
Activation Date: 08-jul-2004 ECOG Participants(requires Adobe Acrobat) |
| E5998 | A Phase II Study of Initial Treatment with Methotrexate in Large
Granular Lymphocytic (LGL) Leukemia
Activation Date: 16-jul-1999 ECOG Participants(requires Adobe Acrobat) |
| S0325 | A Phase IIb Study of Molecular Responses to Imatinib at Standard or
Increased, or Dasatinib (BMS 354825) (NSC 732517), for Previously
Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic
Phase.
Activation Date: 07-jan-2005 |
| S0521 | A Randomized Trial of Maintenance Versus Observation For Patients
With Previously Untreated Low and Intermediate Risk Acute Promyelomic
Leukemia (APL), Phase III
Activation Date: 22-jan-2008 |
| S0535 | A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin
in Patients with Previously Untreated High-Risk Acute Promyelocytic
Leukemia
Activation Date: 23-jun-2008 |
| Protocol | Title |
|---|---|
| E1405 | Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated
Mantle Cell Lymphoma
Activation Date: 01-may-2007 ECOG Participants(requires Adobe Acrobat) |
| E2402 | A Phase II Study of Cyclosporine in the Treatment of
Angioimmunoblastic T-Cell Lymphoma
Activation Date: 02-sep-2005 ECOG Participants(requires Adobe Acrobat) |
| E2404 | Bevacizumab and CHOP (A-CHOP) in Combination for Patients with
Peripheral T-Cell or Natural Killer Cell Neoplasms
Activation Date: 07-jul-2006 ECOG Participants(requires Adobe Acrobat) |
| E3402 | A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for
Patients with Previously Untreated Stages I and II CD20+ Diffuse
Large Cell Non-Hodgkin's Lymphoma
Activation Date: 10-dec-2004 ECOG Participants(requires Adobe Acrobat) |
| E3404 | Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based
on early [18F] FDG-PET Scanning
Activation Date: 07-apr-2006 ECOG Participants(requires Adobe Acrobat) |
| E4402 | Randomized Phase III Trial Comparing Two Different Rituximab Dosing
Regimens for Patients with Low Tumor Burden Indolent non-Hodgkin's
Lymphoma
Activation Date: 21-nov-2003 |
| S0016 | A Phase III Trial of CHOP + Rituximab vs CHOP + Iodine-131-Labeled
Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly
Diagnosed Follicular Non-Hodgkin's Lymphomas
Activation Date: 08-mar-2006 |
| Protocol | Title |
|---|---|
| E1602 | A Randomized Phase II Trial of Multi-epitope Vaccination with
Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for
Patients with Metastatic Melanoma
Activation Date: 21-mar-2005 ECOG Participants(requires Adobe Acrobat) |
| E1697 | Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage
T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A, 3 (microscopic)
Melanoma
Activation Date: 22-dec-1998 |
| E2602 | A Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with
Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor.
Activation Date: 05-sep-2003 ECOG Participants(requires Adobe Acrobat) |
| S0438 | A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772)
with Either CCI-779 (Temsirolimus; NSC-683864) or R115777
(Tipifarnib; NSC-702818) in Metastatic Melanoma
Activation Date: 11-jun-2008 |
| Protocol | Title |
|---|---|
| 10104 | Phase III Randomized Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for
Multiple Myeloma
Activation Date: 18-jan-2006 |
| E1A05 | Randomized Phase III Trial of Consolidation Therapy with
Bortezomib(Velcade), CC-5013 & Dexamethasone(VRD) VS.
Bortezomib(Velcade) & Dexamethasone(VD) for Patients With Multiple
myeloma who have completed a Dexamethasone Based Induction Regimen.
Activation Date: 06-sep-2007 |
| E1A06 | An Intergroup Phase III Randomized Controlled Trial Comparing
Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan,
Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed
Myeloma Patients Who Are Not Candidates for High Dose Therapy
Activation Date: 29-feb-2008 |
| E3A05 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on
Patients Considered for Studies of Plasma Cell Disorders
Activation Date: 30-aug-2006 ECOG Participants(requires Adobe Acrobat) |
| JMY10 | A Randomized Phase III Study of Thalidomide and Prednisone as
Maintenance Therapy Following Autologous Stem Cell Transplant in
Patients with Multiple Myeloma
Activation Date: 16-dec-2005 |
| S0777 | A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813 and
Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239),
Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in
Patients with Previously Untreated Multiple Myeloma without an Intent
for Immediate Autologous Stem Cell Transplant
Activation Date: 08-apr-2008 Suspended: 13-may-2008 |
| Protocol | Title |
|---|---|
| E5597 | Phase III Chemoprevention Trial of Selenium Supplementation in
Persons with Resected Stage I Non Small Cell Lung Cancer
Activation Date: 06-oct-2000 |
| Protocol | Title |
|---|---|
| E2Z04 | Quality of Life in Younger Breast cancer Survivors
Activation Date: 25-oct-2005 ECOG Participants(requires Adobe Acrobat) |
| Protocol | Title |
|---|---|
| 30610 | A Phase III Comparison of Thoracic Radiotherapy Regimens with
Cisplatin and Etoposide in Limited Small Cell Lung Cancer
Activation Date: 21-mar-2008 |
| E1504 | Phase II Study of C225 (Cetuximab) for the Treatment of Patients with
Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC
Features
Activation Date: 10-aug-2005 ECOG Participants(requires Adobe Acrobat) |
| E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without
Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm)
- IIIA Non-Small Cell Lung Cancer (NSCLC)
Activation Date: 01-jun-2007 |
| RTOG 0617 | A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus
High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and
Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB
Non-Small Cell Lung Cancer
Activation Date: 10-dec-2007 |
| S0424 | Molecular Epidemiology Case-Series of Non-small Cell Lung Cancer in
Smoking and Non-Smoking Women and Men
Activation Date: 01-oct-2005 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 07/05/08